Skip to main content
OpenTrials
Completed

NCT Number: NCT05642923

Post-COVID-19 Chronic Fatigue Syndrome

Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post-COVID-19 Syndrome COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Disease Attributes Infections Lung Diseases Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral Post-Acute COVID-19 Syndrome Post-COVID Syndrome Post-Infectious Disorders RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Asalam

Maadi, Cairo Governorate, 11433, Egypt

About this study

It has become increasingly clear that infected patients have symptoms not only in the acute phase, but also after recovery from the initial infection.

A recent meta-analysis including 4828 patients with post-COVID-19 showed that symptoms and post-acute sequelae of SARS-CoV-2 can persist weeks to months after the infection.

These patients who reported persistent symptoms have been termed "long haulers" or described as having long COVID, post-acute COVID-19, persistent COVID-19 symptoms, post COVID-19 manifestations, long-term COVID-19 effects, post-acute sequelae of COVID-19 (PASC), or post-COVID-19 syndrome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age . 18
  • Male or female
  • Post-Covid-19 Fatigue

Exclusion criteria

  • refusal

Treatment and study plan

Synthetic Vitamin B1

Drug

Synthetic Vitamin B1 400 mg per day

Primary outcomes

  1. Fatigue scale

    Time frame: one month

    chalder fatigue scale: the minimum = 0 and maximum values = 33, and whether higher scores mean a worse outcome.

  2. Fatigue scale

    Time frame: two month

    chalder fatigue scale: the minimum = 0 and maximum values = 33, and whether higher scores mean a worse outcome.

  3. Fatigue scale

    Time frame: three month

    chalder fatigue scale: the minimum = 0 and maximum values = 33, and whether higher scores mean a worse outcome.

Secondary outcomes

  1. Incidence of adverse events

    Time frame: 6 months

    Incidence of adverse events

Sponsors and collaborators

Lead sponsor

ClinAmygate

Other

Collaborators

  • As-Salam Center, Maadi, Cairo, Egypt

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Dec 8, 2022
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.